医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Aetna Names Tim Cocchi as Country Manager for Hong Kong Operations

2013年10月09日 AM11:40
このエントリーをはてなブックマークに追加


 

HONG KONG

Aetna (NYSE: AET), a leading global diversified health care solutions company, has named Tim Cocchi, 52, as country manager for its business operations in Hong Kong. The appointment is effective immediately.

In this new position, Cocchi will be responsible for sales and account management for Aetna’s growing business in Hong Kong and Macau and general management guidance for the company’s Hong Kong office.

“We’re pleased that Tim will be leading our dynamic team in Hong Kong, which is an important growth area for Aetna,” said Larry Hartshorn, Aetna International’s interim general manager, Greater China. “With his deep industry knowledge and years of experience in countries around the world, Tim will help us further expand our role as a major provider of individual and group health care benefits plans for expatriates and local nationals.”

Cocchi brings to Aetna more than 30 years’ experience in the employee benefits and insurance industries, both in the United States and internationally. He began his overseas career in Dubai as AIG’s regional head for group medical and managed care business in the Middle East. He later held similar regional roles stationed in Paris, Tokyo and Athens, where he continued to lead profitable growth in AIG’s Accident & Health lines of business. Most recently, Cocchi worked for AIA in a regional role based in Hong Kong.

Cocchi received an M.B.A. from the University of Connecticut and a B.A. in business administration from Western New England College.

Aetna has maintained offices in Hong Kong since 2007 and employs 48 people there. Through a strategic alliance announced earlier this year, Aetna’s medical insurance policies in Hong Kong are underwritten by Starr International, a leading insurance firm licensed by the Hong Kong Insurance Authority.

About Aetna International

Aetna International is committed to helping create a stronger, healthier global community by delivering comprehensive health benefits and health management solutions worldwide. Aetna International’s expatriate business is one of the industry’s largest and most prominent international health benefits providers, supporting more than 500,000 members worldwide. The organization’s expatriate offerings include medical, dental, vision, life, disability and emergency assistance. Aetna International’s health management business collaborates with health care systems, government entities and plan sponsors around the world to design and build locally applied health management solutions to improve health, quality and cost outcomes.

About Aetna

Aetna is one of the United States’ leading diversified health care benefits companies, serving an estimated 44 million people with information and resources to help them make better informed decisions about their health care. Aetna offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, and medical management capabilities, Medicaid health care management services, workers’ compensation administrative services and health information technology products and services. Aetna’s customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups and expatriates. For more information, see www.aetna.com.

CONTACT

Aetna
Vicky Lee, +852-2860-8012
Hong Kong
LeeV3@aetna.com
or
Marnie
Goodman, +1-860-273-2314
United States
GoodmanM2@aetna.com

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続